相关实验视频

Updated: May 5, 2026

LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism

LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism

Published on: April 4, 2016

红细胞分布宽度/血小板比率预测了与代谢功能障碍相关的脂肪性肝病相关的补偿性晚期慢性肝病的减补

Ming-Hua Zheng¹, Amedeo Lonardo²

¹Department of Hepatology, MAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China. zhengmh@wmu.edu.cn.

World journal of gastroenterology

|January 22, 2025

概括

红细胞分布宽度 (RDW) /血小板比率 (RPR) 是一个具有成本效益的,非侵入性的生物标志物,可以预测与代谢功能障碍相关的脂肪性肝病 (MASLD) 相关的补偿性晚期慢性肝病 (cACLD) 脱补偿. 需要进一步的研究来确认其在风险分层中的作用.

科学领域:

肝病学肝病学是一种肝病学.
生物标志物发现发现
内部医学内部医学

背景情况:

补偿性晚期慢性肝病 (cACLD) 的预后对于患者管理和临床决策至关重要.
与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个日益关注的问题,心血管疾病是导致死亡的主要原因.
目前用于MASLD-cACLD的生物标志物需要验证,以预测肝脏相关事件,心血管结果和肝外癌症.

研究的目的:

评估红细胞分布宽度 (RDW) /血小板比率 (RPR) 作为预测MASLD相关的cACLD中脱补偿的非侵入性生物标志物.
评估RPR作为一种廉价且广泛可用的替代现有生物标志物的潜力.
探索RPR在分层MASLD-cACLD患者中对各种不良结果的实用性.

主要方法:

达利奥等人进行的研究. 研究了 RDW/血小板比率 (RPR) 作为预测生物标志物.
使用标准全血细胞计:RDW和血小板计数的参数计算RPR.
研究重点是与代谢功能障碍相关的脂肪性肝病 (MASLD) 相关的补偿性晚期慢性肝病 (cACLD) 的患者.

主要成果:

RDW/血小板比率 (RPR) 被确定为一种潜在的非侵入性生物标志物.
RPR是由随时可用的完整血清参数衍生出来的,这使得它具有成本效益.
这项研究强调了RPR在预测MASLD相关的cACLD中的脱补偿方面的潜力.

结论:

RDW/血小板比 (RPR) 可以作为一个有价值的,可访问的工具来预测与MASLD相关的cACLD.
需要进一步进行大规模的多民族研究,以充分确定RPR的作用和意义.
对于预测肝脏相关事件,心血管结果和癌症的RPR验证对于全面的风险分层是必不可少的.

关键词:

肝硬化是肝硬化的一种疾病.肝脏纤维化肝脏纤维化自然过程中的自然过程.预测预测预测预测分层分层是指分层分层.

更多相关视频

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...